It will be interesting to see how the Merck and the Pfizer pill fair in efficacy beyond the 5 days since in the clinical trials Merck and Pfizer started the treatment within five days of symptoms starting and the stats they announced thus far would be based on that. 

Apabetalone's primary endpoint clinical study is "the change in WHO Ordinal Scale for Clinical Improvement at  Day 14." The secondary outcome measure, the same but at day 28.  

Reference: Slide 13 MD&A dated Sept 30, 2021

"Apabetalone’s unique dual-mechanism gives it the potential to benefit patients throughout
COVID-19 disease progression, making it less reliant on ideal detection than current therapies"

Koo